Bluebird Bio Inc. (NASDAQ:BLUE)’s share price shot up 6.6% during mid-day trading on Wednesday . The company traded as high as $54.00 and last traded at $53.80, with a volume of 686,874 shares changing hands. The stock had previously closed at $50.45.

A number of brokerages have issued reports on BLUE. Wedbush reaffirmed an “outperform” rating and issued a $117.00 price objective on shares of Bluebird Bio in a research note on Thursday, May 5th. Cantor Fitzgerald began coverage on shares of Bluebird Bio in a research note on Thursday, June 2nd. They issued a “hold” rating and a $42.00 price objective on the stock. BTIG Research reaffirmed a “buy” rating and issued a $72.00 price objective on shares of Bluebird Bio in a research note on Sunday, April 3rd. Wells Fargo & Co. reaffirmed a “buy” rating on shares of Bluebird Bio in a research note on Thursday, May 5th. Finally, Jefferies Group reaffirmed a “positive” rating and issued a $80.00 price objective on shares of Bluebird Bio in a research note on Thursday, July 14th. One research analyst has rated the stock with a sell rating, six have given a hold rating and twelve have assigned a buy rating to the stock. Bluebird Bio has a consensus rating of “Buy” and a consensus target price of $96.09.

The firm’s market cap is $2.07 billion. The stock’s 50 day moving average is $44.53 and its 200 day moving average is $45.31.

Bluebird Bio (NASDAQ:BLUE) last announced its quarterly earnings results on Wednesday, May 4th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.23) by $0.29. During the same period in the prior year, the business posted ($0.76) EPS. The business had revenue of $1.50 million for the quarter, compared to analysts’ expectations of $4.50 million. The business’s revenue for the quarter was down 76.2% on a year-over-year basis. Equities research analysts anticipate that Bluebird Bio Inc. will post ($5.90) earnings per share for the current fiscal year.

In other Bluebird Bio news, insider David Davidson sold 1,000 shares of the company’s stock in a transaction that occurred on Monday, May 16th. The shares were sold at an average price of $38.73, for a total value of $38,730.00. Following the completion of the transaction, the insider now directly owns 10,600 shares in the company, valued at approximately $410,538. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Philip D. Gregory sold 2,931 shares of the company’s stock in a transaction that occurred on Thursday, June 16th. The shares were sold at an average price of $39.52, for a total transaction of $115,833.12. Following the completion of the transaction, the insider now owns 30,069 shares of the company’s stock, valued at $1,188,326.88. The disclosure for this sale can be found here.

Several large investors have recently bought and sold shares of BLUE. GAM Holding AG purchased a new stake in Bluebird Bio during the fourth quarter worth approximately $2,717,000. New York State Common Retirement Fund raised its stake in Bluebird Bio by 27.8% in the fourth quarter. New York State Common Retirement Fund now owns 171,022 shares of the company’s stock worth $10,983,000 after buying an additional 37,178 shares in the last quarter. ProShare Advisors LLC raised its stake in Bluebird Bio by 6.5% in the fourth quarter. ProShare Advisors LLC now owns 30,869 shares of the company’s stock worth $1,982,000 after buying an additional 1,888 shares in the last quarter. Nationwide Fund Advisors raised its stake in Bluebird Bio by 40.8% in the fourth quarter. Nationwide Fund Advisors now owns 40,800 shares of the company’s stock worth $2,620,000 after buying an additional 11,830 shares in the last quarter. Finally, Rhumbline Advisers raised its stake in Bluebird Bio by 6.0% in the fourth quarter. Rhumbline Advisers now owns 35,855 shares of the company’s stock worth $2,303,000 after buying an additional 2,023 shares in the last quarter.

bluebird bio, Inc is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.